HC Wainwright Predicts Envoy Medical Q1 Earnings

Envoy Medical, Inc. (NASDAQ:COCH) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Envoy Medical in a research report issued on Tuesday, March 31st. HC Wainwright analyst Y. Chen expects that the company will earn ($0.14) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $2.50 target price on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Envoy Medical’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.30) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Envoy Medical in a research report on Tuesday, January 27th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $6.00.

Envoy Medical Stock Performance

NASDAQ COCH opened at $0.71 on Thursday. The company has a market capitalization of $54.20 million, a price-to-earnings ratio of -0.58 and a beta of 2.08. The company’s 50-day simple moving average is $0.68 and its two-hundred day simple moving average is $0.76. Envoy Medical has a one year low of $0.36 and a one year high of $1.91.

Envoy Medical (NASDAQ:COCH) last released its quarterly earnings data on Monday, March 23rd. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.03 million.

Insiders Place Their Bets

In related news, CFO Robert Potashnick bought 212,500 shares of the company’s stock in a transaction dated Thursday, February 12th. The shares were acquired at an average price of $0.40 per share, for a total transaction of $85,000.00. Following the completion of the transaction, the chief financial officer directly owned 212,500 shares in the company, valued at $85,000. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mona Chetan Patel purchased 312,500 shares of Envoy Medical stock in a transaction that occurred on Thursday, February 12th. The shares were bought at an average price of $0.40 per share, with a total value of $125,000.00. Following the transaction, the director owned 332,500 shares in the company, valued at approximately $133,000. The trade was a 1,562.50% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last quarter, insiders have acquired 20,433,650 shares of company stock valued at $8,173,460. 5.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Envoy Medical

Several hedge funds and other institutional investors have recently made changes to their positions in COCH. Focus Partners Wealth acquired a new stake in shares of Envoy Medical in the first quarter worth approximately $276,000. Geode Capital Management LLC increased its position in shares of Envoy Medical by 111.3% during the fourth quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock worth $65,000 after purchasing an additional 51,813 shares in the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new position in Envoy Medical in the 3rd quarter valued at $60,000. Hedge funds and other institutional investors own 8.59% of the company’s stock.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.